EXCLUSIVE: Turkish Industry Pleads For Value-Based Approach
This article was originally published in PharmAsia News
At the beginning of a new year, the Turkish Association of Research Based Pharmaceutical Companies (AIFD) is asking the government to adopt a “value based” approach to healthcare instead of focusing on costs and prices. In an exclusive interview, AIFD Secretary General and Chief Operating Officer Osman Kara highlights the potential of innovative pharmaceuticals and said that with a transparent and sustainable system, the industry could help Turkey to become a regional hub for healthcare.
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.